XBiotech
XBIT
56 hedge funds and large institutions have $66.6M invested in XBiotech in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 11 closing their positions.
0.97% less ownership
Funds ownership: 14.68% → 13.71% (-0.97%)
10% less capital invested
Capital invested by funds: $74M → $66.6M (-$7.38M)
14% less funds holding
Funds holding: 65 → 56 (-9)
21% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 24
47% less call options, than puts
Call options by funds: $412K | Put options by funds: $780K
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.83M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.41M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$536K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$419K |
| 5 |
State Street
Boston,
Massachusetts
|
+$397K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.65M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$2.01M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$997K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$508K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$460K |
XBIT Hedge Fund Activity: Q2 2021 in Review
56 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2021, worth a combined $66.6M — down 10% from $74M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of XBIT and 2 opened new positions — a net loss of 9 holders — while 24 trimmed existing stakes and 19 added.
The largest buyer was Vanguard Group, adding an estimated $1.83M. The largest seller was BlackRock, cutting an estimated $2.65M.
- 56 institutional investors held XBiotech (XBIT) as of Q2 2021, down from 65 in Q1 2021.
- Funds reported $66.6M of XBiotech stock for Q2 2021, down 10% quarter-over-quarter.
- 2 funds opened new XBiotech positions in Q2 2021 and 11 closed out, a net change of -9 holders.
- The largest XBiotech buyer in Q2 2021 was Vanguard Group, an estimated $1.83M added.
- The largest XBiotech seller in Q2 2021 was BlackRock, an estimated $2.65M sold.
Based on aggregated 13F filings for Q2 2021.